UMB Data Catalog

A project of the Health Sciences and Human Services Library

Filter by

of 1 Next >
Results Found: 1
  • UMB Dataset

    Assessment of the Real-World Safety Profile of Vedolizumab Using the United States Food and Drug Administration Adverse Event Reporting System

    Authors
    Raymond K. Cross
    Michael Chiorean
    Francis Vekeman
    Yongling Xiao
    3 more author(s)...
    Description

    For two decades the standard drug therapy for patients with Crohn’s disease (CD) and ulcerative colitis (UC) has been anti-tumor necrosis factor agents (anti-TNFs) such as adalimumab (Humira), certolizumab pegol (Cimzia), infliximab (Remicade) and several others. More recently, vedolizumab (Entyvio) has entered the market as the first gut-selective integrin blocker that offers an alternative treatment...

    Subject
    Colitis, Ulcerative/drug therapy
    Crohn Disease/drug therapy
    Drug-Related Side Effects and Adverse Reactions
    Access Rights
    Approval required